Skip to content

Epidemiology and burden

TL;DR — Hypertension is the leading single risk factor for attributable death and disability worldwide: 10.8 million deaths (95% UI 9.51–12.1), 19.2% of all deaths, were attributable to high systolic blood pressure in 2019 (GBD 2019 Risk Factors, PMID 33069327), and high systolic pressure accounted for 8.4% (6.9–10.0) of all global DALYs in 2023, ahead of every other risk (GBD 2023, PMID 41092926). The number of affected adults aged 30–79 doubled between 1990 and 2019 to 1.28 billion on a flat age-standardised prevalence, so the growth is demographic (NCD-RisC 2021, PMID 34450083). The defining epidemiological fact is not prevalence but leakage: globally 59% of women and 49% of men with hypertension have been diagnosed and 23%/18% are controlled (NCD-RisC 2021, PMID 34450083); across 44 low- and middle-income countries the cascade runs 73.6% ever measured → 39.2% diagnosed → 29.9% treated → 10.3% controlled (Geldsetzer 2019, PMID 31327566). Control is not monotonically improving even in high-income settings: US control rose to 53.8% in 2013–2014 and then fell to 43.7% by 2017–2018 (Muntner 2020, PMID 32902588).

Global prevalence

Estimate Value Source
Adults 30–79 with hypertension, 1990 331M women (95% CrI 306–359), 317M men (292–344) (NCD-RisC 2021, PMID 34450083)
Adults 30–79 with hypertension, 2019 626M women (584–668), 652M men (604–698) (NCD-RisC 2021, PMID 34450083)
Global adult prevalence, 2010 31.1% (95% CI 30.0–32.2); 1.39 billion (1.34–1.44) people (Mills 2016, PMID 27502908)
Prevalence, high-income vs LMIC, 2010 28.5% vs 31.5% (Mills 2016, PMID 27502908)
Age-standardised prevalence trend, 1990–2019 Stable globally; fell in high-income regions, rose in East/South/Southeast Asia, Oceania, sub-Saharan Africa (NCD-RisC 2021, PMID 34450083; Zhou 2021, PMID 34050340)
Residual lifetime risk from age 55 or 65 ~90%; lifetime probability of antihypertensive drug use 60% (Vasan 2002, PMID 11866648)

Between 2000 and 2010, age-standardised prevalence fell 2.6% in high-income countries and rose 7.7% in low- and middle-income countries; over the same interval control rose from 17.9% to 28.4% in high-income countries but fell slightly, 8.4% to 7.7%, in LMICs (Mills 2016, PMID 27502908). By 2019 prevalence exceeded 50% for women in two countries and men in nine, concentrated in central and eastern Europe, central Asia, Oceania and Latin America (NCD-RisC 2021, PMID 34450083).

The care cascade

The cascade is the organising concept of hypertension epidemiology, because every step leaks.

Step 44 LMICs, 1.1M adults (Geldsetzer 2019, PMID 31327566) Global, 2019 (NCD-RisC 2021, PMID 34450083)
Ever had BP measured 73.6% (95% CI 72.9–74.3) —
Diagnosed 39.2% (38.2–40.3) 59% women / 49% men
Treated 29.9% (28.6–31.3) 47% women / 38% men
Controlled 10.3% (9.6–11.0) 23% women / 18% men

Losses are patterned. Being a woman, older, more educated, wealthier and a non-smoker was positively associated with attaining each cascade step; sub-Saharan African countries performed worst relative to their GDP per capita while Bangladesh, Brazil, Costa Rica, Ecuador, Kyrgyzstan and Peru outperformed theirs on every step (Geldsetzer 2019, PMID 31327566). Country health-system preparedness indicators correlate with quality of cardiovascular risk-factor care across the same survey set (Davies 2020, PMID 33170842). Simulating cascade improvement across those 44 countries shows the largest absolute gains accrue to the poorest wealth quintiles — 29.1 CVD cases averted per 1,000 people with hypertension in the bottom quintile versus 17.2 in the top, in lower-middle-income countries — so closing the cascade is also an equity intervention (Stein 2024, PMID 38278990).

Best-performing countries in 2019 (treatment >70%, control >50%) were South Korea, Canada and Iceland, followed by the USA, Costa Rica, Germany, Portugal and Taiwan; treatment was under 25% for women and 20% for men in Nepal, Indonesia and several sub-Saharan African and Oceanian countries (NCD-RisC 2021, PMID 34450083).

The reversal in high-income control

US control (<140/90) among adults with hypertension rose from 31.8% (95% CI 26.9–36.7) in 1999–2000 to 48.5% (45.5–51.5) in 2007–2008, plateaued at 53.8% (48.7–59.0) in 2013–2014, then declined to 43.7% (40.2–47.2) in 2017–2018 (Muntner 2020, PMID 32902588). Control was strongly conditioned on access: 49.1% among those with a healthcare visit in the past year versus 8.0% without (adjusted prevalence ratio 5.23, 95% CI 2.88–9.49), and 48.4% versus 26.5% with and without a usual facility (Muntner 2020, PMID 32902588). The comorbidity mix has also worsened: among US adults with hypertension, diabetes prevalence rose from 17.2% (1999–2000) to 27.8% (2021–2023), concurrent diabetes plus hyperlipidaemia nearly doubled from 12.5% to 21.3%, and only 26.3% (95% CI 20.8–32.6) of people with all three conditions had all three controlled — unchanged for over a decade (Lee 2025, PMID 41295934).

Young adults are the sharpest failure. In 2021–2023, 21.3% of US adults aged 18–39 (20.4 million) met stage 1/2 criteria, of whom 28.3% were aware and 5.6% controlled to <130/80; awareness and control declined after 2013–2014, and lower rates of having a routine care source explained only 7–16% of the age gap (Tang 2025, PMID 40156902). Among adults aged 20–44, hypertension prevalence was 9.3% (2009–2010) and 11.5% (2017–2020), with persistently high rates in Black adults (16.2% → 20.1%) and significant increases in Mexican American and other Hispanic adults (Aggarwal 2023, PMID 36871237). GBD analysis makes the same point globally for younger adults (Li 2025, PMID 40497517).

Sex, and the life course

Blood pressure trajectories are not simply shifted in time between women and men. In sex-specific longitudinal modelling of 144,599 observations from 32,833 participants across four US community cohorts spanning ages 5–98 and 43 years of follow-up, women showed a steeper rise in systolic pressure, diastolic pressure, mean arterial pressure and pulse pressure than men beginning as early as the third decade, and the differences persisted after adjustment for other cardiovascular risk factors (Ji 2020, PMID 31940010). This displaces the older framing in which women's vascular ageing "lags" men's by 10–20 years, and it is one of the clearest arguments that sex-specific reference trajectories, not sex-neutral thresholds, are the right analytic object (Ji 2022, PMID 35175845; Shangguan 2026, PMID 42185679). Life-course systolic trajectories across eight UK cohorts show the same structure at the population level (Wills 2011, PMID 21695075).

Blood pressure also tracks strongly from childhood. Meta-regression of 50 cohorts (617 systolic data points) gave average tracking correlations of 0.38 systolic and 0.28 diastolic, rising with baseline age and falling with follow-up length (Chen 2008, PMID 18559702). Over 38 years in the Young Finns cohort, the odds ratio for maintaining elevated pressure or hypertension was 2.16 (95% CI 1.95–2.39); the probability of reverting from stage 2 hypertension to normal pressure by midadulthood was 0.23 (0.19–0.26) in males versus 0.58 (0.52–0.62) in females, and adolescence rather than childhood emerged as the period after which reversion becomes unlikely (Meng 2025, PMID 39495520; Iiskala 2026, PMID 41431974). Childhood pressure predicts self-reported adult hypertension directly (Urbina 2019, PMID 31067199; Baker-Smith 2025, PMID 39196350).

Regional detail: sub-Saharan Africa

Pooling 33 surveys and 110,414 participants published 2000–2013 gave a sub-Saharan African hypertension prevalence of 30% (95% CI 27–34) — 16%, 26%, 35% and 44% at mean participant ages of 30, 40, 50 and 60 — with awareness 27% (23–31), treatment 18% (14–22) and control 7% (5–8) (Ataklte 2015, PMID 25385758). More recent syntheses of uncontrolled hypertension in the region, in general populations and in people with comorbidities, report the same shape (Aytenew 2024, PMID 38870163; Mohamed 2021, PMID 34903530), and the drug evidence base specific to the region has been assembled separately because the trial literature is largely non-African (Seeley 2020, PMID 32216794). Hypertension in people living with HIV is a distinct and growing subpopulation across the region (Chen 2024, PMID 39039244; Isaac Derick 2023, PMID 37182060).

Inequality within countries

Neighbourhood deprivation tracks hypertension closely. Across 1,157 neighbourhoods and 56,387 middle-aged adults in one US county, hypertension prevalence was 50.7% in the most-deprived versus 25.5% in the least-deprived quintile, with a lower treatment rate in the most-deprived (61.3% vs 64.5%); 63% of predominantly Black neighbourhoods had prevalence >35% combined with treatment <70%, versus 11.8% of neighbourhoods with ≤5% Black patients; deprivation index plus neighbourhood racial composition accounted for 91–98% of the spatial variation in diagnosed prevalence (Blazel 2024, PMID 39177999). US state-level control varies substantially (He 2024, PMID 37877903).

Attributable burden

Metric Value Source
Deaths attributable to high SBP, 2019 10.8M (95% UI 9.51–12.1), 19.2% of all deaths — the leading Level 2 risk (GBD 2019 Risk Factors, PMID 33069327)
Leading risk for DALYs at ages 50–74 and ≥75, 2019 High systolic blood pressure (GBD 2019 Risk Factors, PMID 33069327)
Share of all global DALYs, 2023 8.4% (6.9–10.0), the leading Level 3 risk (GBD 2023, PMID 41092926)
Deaths attributable to SBP >115 mm Hg, 2015 8.5M, 88% in LMICs (Zhou 2021, PMID 34050340)
Stroke burden attributable to high SBP Dominant modifiable contributor (GBD 2021 Stroke Risk Factors, PMID 39304265)

The dose–response underlying all of this is the Prospective Studies Collaboration: in one million adults with no prior vascular disease and 12.7 million person-years, each 20 mm Hg higher usual systolic pressure was associated with more than a twofold higher stroke death rate and a twofold higher ischaemic heart disease death rate at ages 40–69, with no threshold detectable to 115/75 mm Hg; proportional effects halve by ages 80–89 but absolute risk differences grow (Lewington 2002, PMID 12493255). See risk and outcomes.

Economics

Modelling scale-up of hypertension care across 24 low- and middle-income countries over 30 years projected 2.6 million averted cardiovascular events and 1.2 million averted deaths (7% of expected cardiovascular deaths) at a ≥140 mm Hg treatment cut-point, with 68% of the benefit coming from treating people with SBP ≥160 mm Hg; net economic benefit was positive at some cut-point in 10 of the 12 highest-income but only 3 of the 12 lowest-income countries in the set, and in the lowest-income countries treating from ≥160 mm Hg maximised net benefit (Hutchinson 2024, PMID 38626959). That result is uncomfortable and important: the economically optimal threshold in the poorest settings is higher than the clinically optimal one, which is a resource-allocation finding, not a physiological one. National cost-of-illness studies illustrate the domestic burden (Atkins 2024, PMID 39580704; Daroudi 2025, PMID 40484429), and pharmacist prescribing has been evaluated for cost-effectiveness in the US (Dixon 2023, PMID 37921763).

Measurement caveats on all of the above

Prevalence estimates depend on the threshold. Applying 2017 ACC/AHA criteria rather than JNC7 raised US crude prevalence from 31.9% to 45.6% without much changing the proportion recommended drug treatment (34.3% → 36.2%) (Muntner 2018, PMID 29133599). They also depend on measurement protocol: most surveys use two or three seated office readings, which will misclassify white-coat and masked phenotypes in both directions (see definition, measurement and diagnosis), and self-reported awareness and treatment are subject to recall and social-desirability error. Whether NHANES is an outlier among US control estimates has itself been argued (Egan 2023, PMID 37967159).

Open questions

  • Why did US control peak in 2013–2014 and fall, when drug availability, generic pricing and guideline attention all improved over the same interval? (Muntner 2020, PMID 32902588)
  • Is the young-adult control failure — 5.6% controlled among 18–39-year-olds with stage 1/2 hypertension — a care-access problem, a labelling problem, or a genuine absence of perceived risk? Routine-care-source differences explain only 7–16% (Tang 2025, PMID 40156902).
  • What accounts for LMIC control falling between 2000 and 2010 while treatment rose? (Mills 2016, PMID 27502908)
  • Does the economically optimal ≥160 mm Hg cut-point in the poorest countries reflect a genuine efficiency frontier or under-costed long-run benefits? (Hutchinson 2024, PMID 38626959)
  • How much of the measured global prevalence gradient is real and how much is protocol heterogeneity between the 1,201 contributing studies? (NCD-RisC 2021, PMID 34450083)
  • If systolic pressure rises faster in women from the third decade onwards, should thresholds and risk equations be sex-specific rather than sex-neutral? The 2026-09-01 PubMed and ClinicalTrials.gov searches located sex-stratified analyses but no trial randomising sex-specific diagnostic or treatment thresholds (Ji 2020, PMID 31940010).
  • Adolescence, not childhood, is where the probability of reverting to normal pressure collapses — does that identify a window for population intervention, and has anything been trialled in it? (Meng 2025, PMID 39495520)

References

  1. GBD 2019 Risk Factors Collaborators. Global burden of 87 risk factors in 204 countries and territories, 1990-2019. Lancet. 2020;396:1223-1249. PMID 33069327
  2. GBD 2023 Disease and Injury and Risk Factor Collaborators. Burden of 375 diseases and injuries... 1990-2023. Lancet. 2025;406:1873-1922. PMID 41092926
  3. NCD Risk Factor Collaboration (NCD-RisC). Worldwide trends in hypertension prevalence and progress in treatment and control from 1990 to 2019. Lancet. 2021;398:957-980. PMID 34450083
  4. Geldsetzer P, et al. The state of hypertension care in 44 low-income and middle-income countries. Lancet. 2019;394:652-662. PMID 31327566
  5. Muntner P, et al. Trends in Blood Pressure Control Among US Adults With Hypertension, 1999-2000 to 2017-2018. JAMA. 2020;324:1190-1200. PMID 32902588
  6. Mills KT, et al. Global Disparities of Hypertension Prevalence and Control. Circulation. 2016;134:441-50. PMID 27502908
  7. Zhou B, et al. Global epidemiology, health burden and effective interventions for elevated blood pressure and hypertension. Nat Rev Cardiol. 2021;18:785-802. PMID 34050340
  8. Vasan RS, et al. Residual lifetime risk for developing hypertension in middle-aged women and men. JAMA. 2002;287:1003-10. PMID 11866648
  9. Davies JI, et al. Association between country preparedness indicators and quality clinical care for cardiovascular disease risk factors in 44 lower- and middle-income countries. PLoS Med. 2020;17:e1003268. PMID 33170842
  10. Stein DT, et al. Hypertension care cascades and reducing inequities in cardiovascular disease in low- and middle-income countries. Nat Med. 2024;30:414-423. PMID 38278990
  11. Lee HH, et al. Trends in Prevalence, Treatment, and Control of Cardiometabolic Risk Factors Among Adults With Hypertension in the United States, 1999-2023. J Am Coll Cardiol. 2025;86:2577-2593. PMID 41295934
  12. Tang R, et al. Trends in Hypertension Prevalence, Awareness, Treatment, and Control Among US Young Adults, 2003-2023. Am J Hypertens. 2025;38:551-559. PMID 40156902
  13. Aggarwal R, et al. Cardiovascular Risk Factor Prevalence, Treatment, and Control in US Adults Aged 20 to 44 Years, 2009 to March 2020. JAMA. 2023;329:899-909. PMID 36871237
  14. Li F, et al. Cardiovascular Disease Attributable to High Systolic Blood Pressure in Younger Adults Requires Greater Attention. J Am Heart Assoc. 2025;14:e041964. PMID 40497517
  15. Blazel MM, et al. Neighborhood-Level Disparities in Hypertension Prevalence and Treatment Among Middle-Aged Adults. JAMA Netw Open. 2024;7:e2429764. PMID 39177999
  16. He S, et al. State-Level Hypertension Prevalence and Control Among Adults in the U.S. Am J Prev Med. 2024;66:46-54. PMID 37877903
  17. GBD 2021 Stroke Risk Factor Collaborators. Global, regional, and national burden of stroke and its risk factors, 1990-2021. Lancet Neurol. 2024;23:973-1003. PMID 39304265
  18. Lewington S, et al. Age-specific relevance of usual blood pressure to vascular mortality. Lancet. 2002;360:1903-13. PMID 12493255
  19. Hutchinson B, et al. Scaling hypertension treatment in 24 low-income and middle-income countries. BMJ Open. 2024;14:e071036. PMID 38626959
  20. Atkins ER, et al. The cost of treating hypertension in Australia, 2012-22. Med J Aust. 2024;221:612-616. PMID 39580704
  21. Daroudi R, et al. Economic burden of hypertension in Iran. BMJ Open. 2025;15:e099322. PMID 40484429
  22. Dixon DL, et al. Cost-Effectiveness of Pharmacist Prescribing for Managing Hypertension in the United States. JAMA Netw Open. 2023;6:e2341408. PMID 37921763
  23. Muntner P, et al. Potential US Population Impact of the 2017 ACC/AHA High Blood Pressure Guideline. Circulation. 2018;137:109-118. PMID 29133599
  24. Egan BM, et al. Trends in Hypertension Control Among United States Adults: Is NHANES the Outlier? Hypertension. 2023;80:2544-2546. PMID 37967159
  25. O'Connell SS, et al. Global trends in hypertension prevalence, awareness, treatment, and control. Curr Opin Nephrol Hypertens. 2026;35:174-180. PMID 41495934
  26. Qiu W, et al. Hypertension awareness, treatment, control, and prognosis: insights from China PEACE. Hypertens Res. 2025;48:1012-1023. PMID 39639124
  27. Cao X, et al. Trends and sociodemographic patterns in hypertension prevalence and treatment in China. Med. 2025;6:100808. PMID 40865522
  28. Ji H, et al. Sex Differences in Blood Pressure Trajectories Over the Life Course. JAMA Cardiol. 2020;5:19-26. PMID 31940010
  29. Ji H, et al. Sex Differences in Myocardial and Vascular Aging. Circ Res. 2022;130:566-577. PMID 35175845
  30. Shangguan S, et al. Endogenous and exogenous determinants of sex differences in blood pressure. NPJ Cardiovasc Health. 2026;3. PMID 42185679
  31. Wills AK, et al. Life course trajectories of systolic blood pressure using longitudinal data from eight UK cohorts. PLoS Med. 2011;8:e1000440. PMID 21695075
  32. Chen X, et al. Tracking of blood pressure from childhood to adulthood: a systematic review and meta-regression analysis. Circulation. 2008;117:3171-80. PMID 18559702
  33. Meng Y, et al. Tracking and Transition Probability of Blood Pressure From Childhood to Midadulthood. JAMA Pediatr. 2025;179:34-45. PMID 39495520
  34. Iiskala F, et al. Life-Course Blood Pressure Levels, 38-Year Tracking, and Prediction of Hypertension. J Am Heart Assoc. 2026;15:e041805. PMID 41431974
  35. Urbina EM, et al. Relation of Blood Pressure in Childhood to Self-Reported Hypertension in Adulthood. Hypertension. 2019;73:1224-1230. PMID 31067199
  36. Baker-Smith CM. Tracking of blood pressure levels from childhood. Pediatr Nephrol. 2025;40:367-376. PMID 39196350
  37. Ataklte F, et al. Burden of undiagnosed hypertension in sub-Saharan Africa: a systematic review and meta-analysis. Hypertension. 2015;65:291-8. PMID 25385758
  38. Aytenew TM, et al. Uncontrolled hypertension among hypertensive patients in Sub-Saharan Africa. PLoS One. 2024;19:e0301547. PMID 38870163
  39. Mohamed SF, et al. Prevalence of uncontrolled hypertension in people with comorbidities in sub-Saharan Africa. BMJ Open. 2021;11:e045880. PMID 34903530
  40. Seeley A, et al. Pharmacotherapy for hypertension in Sub-Saharan Africa: a systematic review and network meta-analysis. BMC Med. 2020;18:75. PMID 32216794
  41. Chen A, et al. Hypertension among people living with HIV in sub-Saharan Africa. Sci Rep. 2024;14:16858. PMID 39039244
  42. Isaac Derick K, et al. Prevalence, Awareness, Treatment, Control of Hypertension... in Sub-Saharan Africa. Cureus. 2023;15:e37422. PMID 37182060